oncolytic | Media Room | PressRelease.com

Press Release Jul 19, 2016

Cancer Virotherapy Medicine Received the Grant From European Commission in Order to Initiate the Commercialization in the EU Markets

World Boxing Champion Mairis Briedis Joins Cancer Fighting Team

Oncolytics Biotech® Inc. Receives No Objection Letter from Health Canada to Conduct Phase 3 Trial of REOLYSIN® in Head and Neck Cancers

Oncolytics Biotech Inc announced that it has received a No Objection Letter from Health Canada to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin.